April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Th17/IL17 Mediates Autoimmunity-Dependent Corneal Lymphangiogenesis in Dry Eye Disease
Author Affiliations & Notes
  • S. Chauhan
    Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • Y. Jin
    Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • S. Goyal
    Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • A. Okanobo
    Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • H. Lee
    Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • D. R. Saban
    Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • R. Dana
    Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  S. Chauhan, Schepens Eye Res Inst, P; Y. Jin, None; S. Goyal, None; A. Okanobo, None; H. Lee, None; D.R. Saban, None; R. Dana, Schepens Eye Res Inst, P.
  • Footnotes
    Support  NIH EY19098, Research to Prevent Blindness
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 4312. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Chauhan, Y. Jin, S. Goyal, A. Okanobo, H. Lee, D. R. Saban, R. Dana; Th17/IL17 Mediates Autoimmunity-Dependent Corneal Lymphangiogenesis in Dry Eye Disease. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4312.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Th17 cells are the dominant pathogenic T effectors, causing damage to ocular surface epithelia in dry eye disease. Corneal lymphangiogenesis is a process induced in dry eye which contributes to disease progression. The purpose of this study was to investigate whether autoreactive Th17-secreted-IL17 contributes to corneal lymphangiogenesis in dry eye disease via stimulating the secretion of pro-lymphangiogenic factors by corneal epithelial cells.

Methods: : We first stimulated in vitro the primary human and murine corneal epithelial cells with IL17, and measured the expression levels of VEGF-A, -C and -D transcripts using real time PCR. Murine corneal pellet model was used to study the effects of IL17 pellet on lymphangiogenesis, and VEGF-D pellets were used as controls. Finally using a murine model of dry eye disease, we investigated the effects of in vivo topical blockade of IL17 on corneal lymphangiogenesis and the severity of disease.

Results: : IL17 significantly increased pro-lymphangiogenic VEGF-D secretion by both primary human and murine corneal epithelial cells in vitro. Growth of CD31loLYVE1hi lymphatic vessels in corneas with IL17 pellets was comparable to those in corneas with VEGF-D pellets. In vivo topical blockade of IL17 in dry eye corneas showed a significant reduction in corneal expression of VEGF-D and ingrowth of lymphatic vessels toward the central cornea which were paralleled with a significant decrease in the severity of the disease.

Conclusions: : Our data demonstrate that IL17 is a contributor to lymphangiogenesis in the dry eye cornea via induction of pro-lymphangiogenic VEGF-D. In addition, the findings that in vivo topical IL17 blockade leads to inhibition of lymphangiogenesis and diminished disease severity suggest a potential novel target for the treatment of dry eye disease.

Keywords: cornea: basic science • inflammation • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×